Ken Frazier, Chairman and CEO, Merck & Co., speaks during a meeting of the Economic Club of New York, October 3, 2018.
Brendan McDermid | Reuters
Drugmaker Merck reported a drop in third-quarter profit on Tuesday, hit by a $982 million charge related to its acquisition of Peloton Therapeutics.
Net income fell to $1.90 billion, or 74 cents per share, from $1.95 billion, or 73 cents per share, a year earlier.
Sales rose to $12.40 billion from $10.79 billion.
This article was originally published by Cnbc.com. Read the original article here.